Sarcoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A usually aggressive malignant neoplasm of the soft tissue or bone. It arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels. Sarcomas occur in both children and adults. The prognosis depends largely on the degree of differentiation (grade) of the neoplasm. Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Sarcoma
- Therapeutic area
- Oncology
- sarcoma
- mesenchymal tumor, malignant
- sarcoma
- sarcoma of soft tissue and bone
- sarcoma of the soft tissue and bone
- sarcoma, malignant
- tumour of soft tissue and skeleton
- All therapeutic areas
- Oncology
- Severity
- Severe
- MONDO ID
- MONDO:0005089
- Parent condition
- MONDO:0004992
Related records
Broader conditions (7)
- Cancer
- Cancer or benign tumor
- Disease
- Disease by etiologic mechanism
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (322)
- Adult botryoid rhabdomyosarcoma
- Adult epithelioid sarcoma
- Adult extraskeletal osteosarcoma
- Adult fibrosarcoma
- Adult liposarcoma
- Adult malignant schwannoma
- Adult mesenchymal chondrosarcoma
- Adult myxoid chondrosarcoma
- Adult pleomorphic rhabdomyosarcoma
- Adult vagina botryoid embryonal rhabdomyosarcoma
- Alveolar rhabdomyosarcoma
- Alveolar soft part sarcoma
- Anaplastic sarcoma of the kidney
- Angiosarcoma
- Angiosarcoma of the scalp
- Anus leiomyosarcoma
- Anus rhabdomyosarcoma
- Anus sarcoma
- Aorta angiosarcoma
- Asynchronous multifocal osteogenic sarcoma
Trials (1,601)
- "Exercise Intervention to Increase Physical Activity in Young Sarcoma Survivors (Sport Ist Herzenssache)"
- (SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas
- 11C-Acetate PET/CT Non-FDG-Avid Tumors
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- 18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma
- 5-AminoLevulinic Acid Aided Resection Margins in Sarcoma
- 5-Day Preoperative Radiation for Soft Tissue Sarcoma
- 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
- 68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas
- 68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
- 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
- 89Zr-olaratumab Dosimetry in Participants With PDGFR Alpha Positive Solid Tumours and Soft Tissue Sarcoma
- 9-ING-41 in Patients With Advanced Cancers
- A Checklist (Advanced Care Planning) for The Assessment of Mobility Needs in Patients With Sarcoma
- A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
- A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
- A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors
- A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors
- A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors
Approved drugs (6)
- Doxorubicin hydrochloride
- Olaratumab
- Pazopanib hydrochloride
- Tasonermin
- Tazemetostat hydrobromide
- Trabectedin
Drugs in development (174)
- 6-O-benzylguanine Phase 2
- Abexinostat Phase 1
- ABT-510 Phase 2
- Aldesleukin Phase 1
- Alectinib Phase 2
- Altretamine Phase 1
- Alvocidib Phase 2
- AMG-888 Phase 1
- Amifostine Phase 2
- Atezolizumab Phase 2
- Azacitidine Phase 1
- BCG vaccine Phase 1
- Bempegaldesleukin Phase 2
- Bevacizumab Phase 2
- Bortezomib Phase 2
- Busulfan Phase 3
- Camrelizumab Phase 2
- Carboplatin Phase 3
- Carmustine Phase 2
- Catequentinib Phase 3
Other linked drugs (3)
- Aldoxorubicin
- CTCE-9908
- Valganciclovir